Neurometrix Inc (NASDAQ:NURO) shares reached a new 52-week low on Wednesday . The stock traded as low as $0.98 and last traded at $1.00, with a volume of 34420 shares traded. The stock had previously closed at $1.00.

Separately, Zacks Investment Research downgraded shares of Neurometrix from a “buy” rating to a “hold” rating in a research report on Thursday, September 27th.

The stock has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.09 and a beta of 0.41.

Neurometrix (NASDAQ:NURO) last released its quarterly earnings results on Wednesday, October 17th. The medical device company reported $0.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.34. Neurometrix had a negative net margin of 0.37% and a negative return on equity of 0.90%. The business had revenue of $3.67 million for the quarter. Equities analysts forecast that Neurometrix Inc will post 0.02 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Neurometrix stock. Renaissance Technologies LLC grew its holdings in Neurometrix Inc (NASDAQ:NURO) by 55.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 213,615 shares of the medical device company’s stock after acquiring an additional 75,932 shares during the period. Renaissance Technologies LLC owned 2.90% of Neurometrix worth $284,000 as of its most recent SEC filing. 9.14% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Neurometrix (NURO) Reaches New 12-Month Low at $0.98” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at

About Neurometrix (NASDAQ:NURO)

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Recommended Story: Does the discount rate affect the economy?

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.